New Drug Approvals in China Reach Record High in 2023
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology, as well as musculoskeletal system, alimentary tract and metabolism, blood and blood-forming organ, genito-urinary system and sex hormone, and other therapeutic areas.
It provides approximately 800 varieties of drugs and 20 dosage forms. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations, etc. Further, the company manufactures and trades in medicines, and medical equipment and instruments; and rents properties, as well as wholesales chemicals and active pharmaceutical ingredients. It operates approximately 1,892 chained pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People’s Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
See our Cookie Privacy Policy Here
